Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis.
about
Proteases Revisited: Roles and Therapeutic Implications in Fibrosis.Current and future pharmacological therapies for NAFLD/NASH.Molecular mechanism of obesity-induced 'metabolic' tissue remodeling.Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis.
P2860
Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 March 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antifibrotic effect of pirfeni ...... nonalcoholic steatohepatitis.
@en
Antifibrotic effect of pirfeni ...... nonalcoholic steatohepatitis.
@nl
type
label
Antifibrotic effect of pirfeni ...... nonalcoholic steatohepatitis.
@en
Antifibrotic effect of pirfeni ...... nonalcoholic steatohepatitis.
@nl
prefLabel
Antifibrotic effect of pirfeni ...... nonalcoholic steatohepatitis.
@en
Antifibrotic effect of pirfeni ...... nonalcoholic steatohepatitis.
@nl
P2093
P2860
P356
P1433
P1476
Antifibrotic effect of pirfeni ...... nonalcoholic steatohepatitis.
@en
P2093
Chikara Komiya
Kazuhiko Nakabayashi
Ken-Ichiro Hata
Kenji Ikeda
Kentaro Mori
Kozue Ochi
Kumiko Shiba
Kyoichiro Tsuchiya
Michiko Itoh
Miyako Tanaka
P2860
P2888
P356
10.1038/SREP44754
P407
P577
2017-03-17T00:00:00Z